Drug Profile
ARM 210
Alternative Names: ARM-210; S-48168Latest Information Update: 06 Feb 2024
Price :
$50
*
At a glance
- Originator ARMGO Pharma
- Developer ARMGO Pharma; National Institute of Neurological Disorders and Stroke; Servier
- Class Small molecules
- Mechanism of Action Ryanodine receptor calcium release channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Polymorphic catecholergic ventricular tachycardia
- Phase I Congenital structural myopathies
- No development reported Duchenne muscular dystrophy; Limb girdle muscular dystrophies; Sarcopenia; X-linked bulbo-spinal atrophy
Most Recent Events
- 29 Jan 2024 Efficacy data from a phase I trial in Congenital structural myopathies released by ARMGO Pharma
- 29 Jan 2024 ARMGO Pharma plans a phase II trial for Congenital structural myopathies
- 29 Jan 2024 Armgo Pharma completes a phase I trial in Congenital structural myopathies in USA (PO) (NCT04141670)